1. Home
  2. PAGS vs IMNM Comparison

PAGS vs IMNM Comparison

Compare PAGS & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

PAGS

PagSeguro Digital Ltd.

HOLD

Current Price

$9.25

Market Cap

2.5B

Sector

Technology

ML Signal

HOLD

Logo Immunome Inc.

IMNM

Immunome Inc.

HOLD

Current Price

$23.15

Market Cap

2.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PAGS
IMNM
Founded
2006
2006
Country
Brazil
United States
Employees
N/A
N/A
Industry
EDP Services
Medicinal Chemicals and Botanical Products
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.5B
2.6B
IPO Year
2017
2020

Fundamental Metrics

Financial Performance
Metric
PAGS
IMNM
Price
$9.25
$23.15
Analyst Decision
Buy
Strong Buy
Analyst Count
5
10
Target Price
$12.00
$32.80
AVG Volume (30 Days)
3.3M
1.8M
Earning Date
05-12-2026
05-08-2026
Dividend Yield
1.42%
N/A
EPS Growth
N/A
51.40
EPS
N/A
N/A
Revenue
N/A
$6,941,000.00
Revenue This Year
$11.07
N/A
Revenue Next Year
$7.26
$1,127.34
P/E Ratio
$7.74
N/A
Revenue Growth
N/A
N/A
52 Week Low
$7.74
$7.96
52 Week High
$12.32
$27.65

Technical Indicators

Market Signals
Indicator
PAGS
IMNM
Relative Strength Index (RSI) 56.29 63.89
Support Level $9.21 $19.28
Resistance Level $9.43 $25.10
Average True Range (ATR) 0.29 1.27
MACD 0.05 0.51
Stochastic Oscillator 81.41 72.67

Price Performance

Historical Comparison
PAGS
IMNM

About PAGS PagSeguro Digital Ltd.

PagSeguro Digital Ltd is a Brazilian-based company that acts as a provider of financial technology solutions focused on Micro-Merchants, Small Companies and Medium-Sized Companies (SMEs), in Brazil. The company provides a range of solutions and tools such as cash-in and cash-out options and provides access to working capital to help to manage its cash flow. It delivers an end-to-end digital ecosystem to address day-to-day financial needs, including receiving and spending funds and managing and growing businesses for clients. The company also offers the Free PagSeguro Digital Account delivering Cash-In Solutions, Online and In-Person Payment Tools, Online Payment Tools; and Web Check Outs offer tokenization, handling of shipping information, and others.

About IMNM Immunome Inc.

Immunome Inc is a biotechnology company focused on developing first-in-class targeted oncology therapies. The company specializes in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics. Its pipeline includes varegacestat, an investigational oral gamma secretase inhibitor that reported positive topline results in the Phase 3 RINGSIDE trial for progressing desmoid tumors; IM-1021, a ROR1 antibody-drug conjugate under evaluation in a Phase 1 trial; and IM-3050, a FAP-targeted radioligand therapy with IND clearance and a planned Phase 1 trial. The company is also advancing preclinical solid tumor ADCs, including IM-1617, IM-1340, and IM-1335.

Share on Social Networks: